Plus   Neg

QuickLogic Q4 Loss Better Than Analysts' Estimates

QuickLogic Corp. (QUIK) Wednesday reported fourth-quarter loss of $3.06 million or $0.37 per share, compared with last year's loss of $3.07 million or $0.45 per share.

Fourth-quarter adjusted loss was $2.4 million or $0.29 per share, compared with $2.6 million or $0.38 per share last year.

Revenues for the fourth quarter were $2.87 million, compared with $3.23 million in the fourth quarter last year.

Analysts polled by Thomson Reuters expected loss of $0.31 per share on revenues of $2.93 million. Analysts' estimates typically exclude special items.

New product revenue was $0.7 million, 47% lower than a year ago, while mature product revenues were $2.2 million in the fourth quarter, compared with $1.9 million last year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT